Climb Bio Will Present Nephrology Data in Denver
The clinical-stage firm will disclose results for two drug candidates at the upcoming ASN Kidney Week conference.
Updated on Oct. 2, 2026 in Biotech
Live Poll
Do you trust that new medical breakthroughs from biotechnology firms will genuinely improve patient health outcomes?
Climb Bio will showcase clinical data for its pipeline of immune-mediated disease treatments at the American Society of Nephrology Kidney Week 2026. These research-stage presentations will cover three distinct kidney conditions occurring October 21-25 in Denver.
Why it matters
The presentations offer insight into the trajectory of the company’s monoclonal antibody candidates, including therapies for IgA nephropathy and primary membranous nephropathy. The findings detail the progress of these investigational drugs as they advance through the clinical pipeline.
The firm is evaluating budoprutug, a low-fucosylated anti-CD19 monoclonal antibody, and CLYM116, an anti-APRIL monoclonal antibody. These molecules are being assessed across three disease areas, with developers also testing a new subcutaneous formulation of budoprutug.
The players
Climb Bio
A clinical-stage biotechnology company focused on developing therapies for immune-mediated diseases.
American Society of Nephrology
A professional society representing kidney specialists that facilitates the sharing of clinical and research data.
The details
Budoprutug functions as a low-fucosylated anti-CD19 monoclonal antibody, a class of lab-engineered proteins designed to flag specific cells for immune system clearance. CLYM116 targets APRIL, a protein associated with the regulation of B-cells that produce antibodies. Both therapies act on underlying immune pathways to address kidney disease, moving beyond symptom management to modulate the systemic immune response.
Timeline
October 21-25, 2026: ASN Kidney Week 2026 takes place in Denver.
October 22, 2026: The scheduled date for the CLYM116 poster presentation.
October 23, 2026: Additional poster sessions for CLYM116 and budoprutug will occur.
October 24, 2026: The budoprutug oral presentation is set for this date.
The Tech Race
The upcoming data release follows the FDA granting Fast Track and Orphan Drug designations to budoprutug for primary membranous nephropathy. This trajectory places the company in active competition with other pipeline developers working on B-cell modulating therapies for systemic autoimmune conditions.
These presentations provide the most recent clinical performance data for individuals monitoring the development of new treatments for IgA nephropathy and lupus. Readers should track the official abstracts published by the American Society of Nephrology during the week of October 21 for specific efficacy benchmarks.
The takeaway
These sessions represent a critical milestone for Climb Bio in validating their monoclonal antibody approach against complex immune-mediated kidney diseases. Interested parties should monitor the society’s post-conference abstract archive for the finalized clinical trial results.
Further reading
For more on the current landscape of experimental therapies, visit Biotech.
Live Poll
Do you trust that new medical breakthroughs from biotechnology firms will genuinely improve patient health outcomes?
